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To investigate whether a principal neutralization epitope exists in hypervariable region 1 (HVR1) within the putative
envelope of hepatitis C virus (HCV), we generated a hyperimmune rabbit serum against a synthetic peptide corresponding
to HVR1 of HCV isolate H77. The reactivity of the serum in the enzyme-linked immunosorbent assay was correlated with
the 13 amino acids (position 398–410) in HVR1. The serum prevented infection with H77 virus in cell cultures but did not
prevent infection with H90 virus, a genetically divergent isolate from the same patient. The study demonstrated that
neutralization of HCV was mediated, in part, by isolate-specific antibody recognizing HVR1. q 1996 Academic Press, Inc.
Hepatitis virus C (HCV) infection is a worldwide health taining antibodies to a synthetic peptide with the se-
problem. It persists in over 80% of infected cases and quence of a specific HVR1 neutralizes a strain of HCV
may result in chronic hepatitis, liver cirrhosis, and hepa- that contains the same HVR 1 sequence.
tocellular carcinoma. The development of an effective A peptide with 21 amino acids (peptide A in Fig. 1A)
vaccine would be the most efficient method to prevent was synthesized based on the published HVR1 sequence
these diseases. However, HCV is known to undergo ge- of strain H77 (12), a pedigreed isolate of HCV, and cou-
netic mutation during infection even within one individual pled with tetanus toxin at the N-terminus. Rabbit 87 re-
(1–3). Hypervariable region 1 (HVR1), the N-terminal 27 ceived two immunizations at 1-month intervals intra-
amino acids within the putative envelope protein E2, dermically, using 500 mg of the conjugated peptide in
comprises the most variable region of the HCV genome complete Freund’s adjuvant, followed by a booster 6
(4, 5). The variation is assumed to be caused by random months later. Serum samples were obtained prior to
mutation and selection of mutants capable of escaping (coded as 87P) and 6 months after injection (coded as
from neutralizing antibodies produced in the patients. We 87I). Serum 87I was reactive in enzyme-linked immu-
previously established in vitro systems for detection of noabsorbent assay (ELISA) against the homologous pep-
HCV infectivity using the human lymphocyte cell lines, tide and the recombinant E1/E2 protein complex ex-
HPBMa10.2 (6, 7) and Daudi cells (8), and demonstrated pressed by a vaccinia vector. In order to locate amino
that anti-HCV antibody can be detected by blocking the acids which affect the reactivity of serum 87I, 4 additional
adsorption of HCV virions to the HPBMa10-2 cells (9) peptides (B, C, D, and E in Fig. 1A) were synthesized and
and by the formation of antigen–antibody complexes tested by ELISA. Microtiter plates were coated overnight
(10). The antibody was isolate-specific and the specificity at 47 with each peptide at a concentration of 5 mg/well
changed over time (9). Recently, Zibert et al. demon- and then blocked for 2 days with phosphate-buffered
strated, employing the adsorption-blocking method, that saline containing 0.2% bovine serum albumin and 1%
the majority of neutralizing antibodies in the patient sera Tween-20 (Sigma). The plates were incubated with serial
were directed against the HVR1 of HCV (11). The study dilutions of serum 87P or serum 87I overnight at 47,
presented here examines whether immune serum con- washed, and incubated with peroxidase-labeled anti-rab-
bit IgG (MBL, Japan) for 2 hr at 377. Enzyme reactions with
substrates were carried out according to the standard
1 To whom correspondence and reprint requests should be ad- procedure. The optical density (OD492) was measured indressed at Department of Bacteriology, Faculty of Medicine, University
a MTP-32 Reader (Corona, Japan). Preimmune serumof Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113, Japan. Fax: 81-3-5684-
9374. 87P was not reactive with any of the peptides. As shown
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tion of buoyant density (10). H90 has been shown to be
positive for anti-HCV C22 and C100 antibodies by ELISA
(9). Both have been shown to be infectious in chimpan-
zees; plasma H77 contained 106.5 50% chimpanzee infec-
tious doses of HCV per milliliter (13) and 1 ml of undiluted
plasma H90 was infectious in a chimpanzee (unpub-
lished data).
To determine the adsorption efficiency of the H77 and
H90 viruses to the cells, plasmas H77 and H90 were
serially diluted in 10-fold increments and 100 ml of each
dilution was inoculated into 1 ml of a suspension of 5 1
105 HPBMa10.2 cells. After incubation for 2 hr at 377, the
cells were washed twice and tested for cell-adsorbed
HCV RNA by reverse transcription (RT)/PCR using nested
primers which detect the E1/E2 region of the HCV ge-
nome. Plasmas H77 and H90 had genome titers of 106/
100 and 105/100 ml, respectively, by end-point dilution
RT/PCR assay, but the adsorption titer was 103/100 ml
for H77 and 101/100 ml for H90 (Fig. 2A). We also checked
the HVR1 sequences of HCV adsorbed by the cells, since
a high level of genetic diversity has been reported for
H77 (14, 15). The HCV genomes adsorbed by the cells
at the dilutions of 1003 for H77 and 1001 for H90 were
RT/PCR-amplified and the products were cloned into
pUC118 (Takara, Japan) and 10–12 subclones were se-
quenced by ABI 373A sequencer with the Taq dye termi-
nator cycle sequencing kit (Perkin–Elmer). For H77, 5 of
12 clones had the HVR 1 amino acid sequence which
was the same as peptide A used for immunization exceptFIG. 1. (A) Amino acid sequences of the synthetic peptides tested
by ELISA. Dashes represent amino acid residues which are identical
to peptide A. Peptides C and D are chimeras composed of sequences
from the HVR1 regions of HCV strains H77 and H90. (B) The reactivity
by ELISA of hyperimmune serum 87I against the synthetic peptides
shown in A. Optical desity (OD492) values were corrected by subtraction
of values obtained with preimmune serum 87P. (l) Peptide A; (s)
peptide B; (h) peptide C; (j) peptide D; (m) peptide E.
in Fig. 1B, immune serum 87 I was reactive with homolo-
gous peptide A and chimeric peptide D (amino-terminal
H90 and carboxy-terminal H77) but not with peptide B
(derived from the sequence of H90) or chimeric peptide
C (amino-terminal H77 and carboxy-terminal H90). The
substitution of three amino acids (positions 395–397),
which were TTA in H77 and SVL in H90, appeared not
to affect the reactivity of the peptide with serum 87I,
suggesting that the 13 amino acids in positions 398 –
410 determined the reactivity. This was confirmed by the
positive reaction of serum 87I with peptide E, consisting
primarily of these amino acids (Fig. 1B). FIG. 2. (A) Adsorption compared with titers of the HCV genome in
In the neutralization test, isolate H77, representing the inocula. The detection of HCV RNA by RT/PCR was performed using
nested primers that amplify the E1/E2 region (nucleotide positionsHCV in the acute-phase plasma, and isolate H90, a ge-
1437–1709) of the HCV genome. (B) Genetic variation in the HVR1netically divergent isolate in a chronic-phase plasma ob-
(between residues 390 and 410) of the cell-adsorbed HCV after expo-tained 13 years after infection from the same patient (12),
sure to dilutions of 1003 for H77 and 1001 for H90. Number of clones
were used as target viruses. H77 has been shown to be with individual sequences among 12 sequences for H77 and among
negative for antibodies to HCV by ELISA, immunoprecipi- 10 sequences for H90 are indicated on the right. Dashes indicate
identity with the published H77 sequence.tation with anti-human immunoglobulin, and determina-
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for one amino acid at position 391 and 7 of 12 clones
retained the sequence common to peptides A, D, and E,
which reacted with the 87I serum. For H90, 5 of the 10
clones had the same sequence as peptide B (Fig. 2B).
To determine whether serum 87I blocks the binding
of HCV to the cells, we examined it in HPBMa10-2 cells
as we reported previously (9). Daudi cells were not em-
ployed for the adsorption inhibition assay since it was
found that virus–antibody complexes could be adsorbed
by Daudi cells, a lineage of B cells, probably through the
Fc receptor. A 100-ml sample of each target virus (at a
1003 dilution for H77 and a 1001 dilution for H90, which
corresponded to one adsorption titer per milliliter; see
above) was incubated overnight at 47 with an equal vol-
ume of a 1:10 dilution of serum 87P or serum 87I pre-
viously heated at 567 for 30 min, inoculated into 1 ml of
a suspension containing 5 1 105 HPBMa10.2 cells, and
incubated for 2 hr at 377. After washing, the cell–ad-
sorbed HCV RNA was assayed by RT/PCR. As shown in
Fig. 3A, serum 87I inhibited the binding of H77 to the
cells (Exp. 1 and Exp. 2 in Fig. 3A). However, in one
experiment among three trials (Exp. 3 in Fig. 3A), cell-
adsorbed HCV RNA was detected following incubation
of H77 with serum 87I. This was probably due to the
sequence heterogenity of the inoculum used (see above).
Serum 87I did not inhibit the binding of H90 to the cells
in any of the three trials.
To further investigate whether the adsorption inhibition
by serum 87I mentioned above was correlated with the
inhibition of viral replication, we performed neutralization
experiments in HPBMa10.2 cells and Daudi cells, whose
culture was continued for 12 days after adsorption to
FIG. 3. (A) Adsorption inhibition assays with HCV strains H77 or
monitor the presence of the intracellular HCV genome. H90 and serum 87P or 87I using HPBMa10-2 cells. Three independent
Treatment of the target viruses with serum 87P or serum experiments (Exp. 1, Exp. 2, and Exp. 3) were carried out as described
in the text. The cell-adsorbed HCV was detected by RT/PCR using87I and inoculation into the cells were carried out in
nested primers detecting the E1/E2 region of the HCV genome. (B)the same manner as described above for the binding-
Neutralization assays with HCV strains H77 or H90 and serum 87P orinhibition assay. Here the concentration of the target vi-
87I in cell culture. Neutralization test was performed in HPBMa10-2
ruses was twofold higher than that for the adsorption cells and Daudi cells as described in the text. The residual infectivity
inhibition. The presence of HCV RNA in the cells was of the virus was evaluated by the detection of intracellular HCV RNA
by RT/PCR using nested primers detecting the E1/E2 region of theexamined by RT/PCR at intervals and the products were
genome. (C) Amino acid sequences of the HVR 1 recovered from thesubjected to direct sequencing. Figure 3B shows the
neutralization experiments shown in B. The RT/PCR products wereresults. Serum 87I inhibited detection of the H77 virus
subjected to direct sequencing. Dashes indicate identity with the amino
later than Day 0 in HPBMa10-2 cells and later than Day acid sequence of peptide A. Asterisks indicate A (alanine) encoded by
3 in Daudi cells, while serum 87P failed to do so in both GCT instead of GCC.
cultures. When neutralization was attempted with the
H90 virus, both serum 87P and serum 87I failed to pre-
vent infection in both cultures. Thus, neutralization by as the sequence representing a major population in the
H77 inoculum (15). Similar results were obtained withserum 87I appeared to be isolate-specific. The cell cul-
tures were sometimes intermittently positive during the Day 0 and Day 12 harvests of Daudi cells. At the nucleo-
tide level, however, the sequence recovered on Day 0course of infection, but such intermittent positivity was
characteristic of HCV-carrier cultures (7). and the sequence recovered on Day 9 from HPBMa10-
2 cells or on Day 12 from Daudi cells differed by oneWe also examined the sequences of HCV strains re-
covered from the neutralization experiments. When nucleotide at position 1517: C for Day 0 and T for Days
9 and 12 (asterisks in Fig. 3C indicate A (alanine) en-HPBMa10.2 cells were incubated with H77 treated with
preimmune serum 87P, the amino acid sequence recov- coded by GCT instead of GCC). The sequence with T
at position 1517 was a minority at adsorption, but thisered from cells harvested on Days 0 and 9 was the same
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sequence was the one that persisted as a selected vari- ACKNOWLEDGMENTS
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